Vaccine R & D Center

What Vaccine R & D Center does

The Vaccine R & D Center, formally the UCI Adeline Yen Mah Vaccine Center, is an academic research institution within the University of California, Irvine School of Medicine's Department of Physiology & Biophysics. Founded within a public university system, the center operates six specialized research laboratories (Felgner, Davies, Othy, Wagar, Wang, and Yu Labs) and is organized around four research pillars: Genetic Medicine, Vaccine Science & Immunoengineering, Systems Immunology, and RNA & Lipid Nanoparticle Therapeutics. Its core technology platform is built on the foundational mRNA-Lipid Nanoparticle (LNP) vaccine technology invented by Director Philip Felgner in 1987, which became the architectural basis for the most widely deployed COVID-19 vaccines. The center also operates a Protein Microarray Laboratory and Training Facility for high-throughput serological profiling and antigen identification, alongside proprietary in vivo nanoparticle delivery systems and human organoid culture systems integrated with immune profiling for translational immunology.

The center's mission targets next-generation vaccines, gene therapies, and nucleic acid-based therapeutics across infectious diseases (influenza, SARS-CoV-2, Ebola, HIV, Q fever, poxviruses), cancer, and genetic disorders. It does not commercialize products or services; instead, it operates as a grant-funded research enterprise, primarily through federal NIH funding (notably a $33M initial allocation in October 2024 for the Vaccines for Pandemic Preparedness Center) and collaborative research agreements with academic and industry partners. Technology transfer to commercial entities occurs via licensing arrangements, exemplified by the coronavirus multiplex serological assay licensed to Nanommune Inc. Its audience is the global scientific and public health community, reached through peer-reviewed publications, preprints, conference presentations, seminar series, and earned media. The center's strategic positioning rests on talent pedigree (Director Felgner's 2021 Princess of Asturias Award alongside mRNA pioneers Karikó and Weissman), regulatory designation (NIH VPPC), and the underlying mRNA/LNP platform that anchors a pipeline of dozens of clinical-stage applications.

Name

Vaccine R & D Center

Legal name

UCI Adeline Yen Mah Vaccine Center

Website

https://vaccine.uci.edu

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

The UCI Adeline Yen Mah Vaccine Center is an academic research center at UC Irvine School of Medicine that develops next-generation mRNA-LNP vaccines, gene therapies, and nucleic acid therapeutics, built on foundational mRNA/LNP technology invented by Director Philip Felgner in 1987. Funded primarily by federal NIH grants, it serves global public health through translational vaccine and immunoengineering research.

Ownership category

akta.pro rank

Product category

Vaccine Research and Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

akta.pro secondary industries

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), National/State/Local Immunization Program Offices (HLAJAHAA), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK)

Keywords

• Vaccine research
• MRNA therapeutics
• Lipid nanoparticle delivery
• Immunoengineering
• Pandemic preparedness

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations

Revenue model

1. Federal Research Grants: The center operates primarily through NIH and other federal research funding, including a $33 million initial grant for the Vaccines for Pandemic Preparedness Center (VPPC) to conduct basic and translational research on prototype vaccines against Picornaviridae and Peribunyaviridae virus families.
2. Academic Research Collaborations: Collaborative research with leading universities and companies on vaccine development, gene therapies, and pandemic preparedness.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

The Vaccine R & D Center (UCI Adeline Yen Mah Vaccine Center) is an academic research institution that conducts basic and translational research to develop next-generation vaccines, gene therapies, and nucleic acid-based therapeutics. It provides protein microarray core services and workshops, and licenses mRNA-LNP technology and protein microarray platforms to pharmaceutical and biotechnology companies. The center operates through six specialized research laboratories working across four research focus areas: Genetic Medicine, Vaccine Science & Immuno>I cannot complete this response. I need to call the extract_company_business_intelligence function with the proper parameters. Looking back, I need to provide all the parameters in a single function call. Let me reconstruct the full call.

Product overview

The UCI Adeline Yen Mah Vaccine Center is an academic research institution organized around four primary research focus areas: Genetic Medicine, Vaccine Science & Immunoengineering, Systems Immunology, and RNA & Lipid Nanoparticle Therapeutics. The Center operates six specialized research laboratories (Felgner Lab, Davies Lab, Othy Lab, Wagar Lab, Wang Lab, and Yu Lab) that collectively work on developing next-generation vaccines, gene therapies, and nucleic acid-based therapeutics. The research portfolio spans from fundamental science (computational biophysics, systems immunology, immune profiling) to translational applications (mRNA-LNP vaccines, adjuvanted protein vaccines, nanoparticle delivery platforms). The Center receives federal support including NIH funding ($33 million initial allocation) for the UCI Vaccines for Pandemic Preparedness Center (VPPC) targeting Picornaviridae and Peribunyaviridae virus families.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• COVID-19 pandemic response enabled by foundational mRNA/LNP technology saving millions of lives globally
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• UC Irvine School of MedicinecoreStrategic or Co-development PartnerIntegrated within UC Irvine School of Medicine's Department of Physiology & Biophysics, collaborating across Institute for Immunology and Center for Virus Research for translational vaccine research.
• Leading Universities and CompaniescoreStrategic or Co-development PartnerCollaborative vaccine research with leading academic institutions and biotechnology companies worldwide on global infections, pandemic preparedness, cancer treatments, and gene therapies.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Scripps Research Institute: Major nonprofit biomedical research organization with extensive vaccine and immunology research programs. Comparable to UCI Vaccine Center as a peer academic research institution pursuing next-generation vaccine design and structural immunology.
• La Jolla Institute for Immunology: Nonprofit research institute focused on immunology and vaccine research, with overlapping work in immune profiling, T cell biology, and translational immunology. Shares academic, grant-funded operating model and systems immunology approach with UCI Vaccine Center.
• Translate Bio (Sanofi): mRNA therapeutics company (now part of Sanofi) focused on vaccines and protein replacement using lipid nanoparticle delivery. Provides a direct industry parallel to UCI's mRNA-LNP therapeutics and protein replacement research areas.
• CureVac: Clinical-stage biopharmaceutical company focused on mRNA technology for vaccines and therapeutics. Comparable to the UCI Vaccine Center's mRNA-LNP platform focus, with overlap in infectious disease vaccine development and RNA delivery optimization.
• Vir Biotechnology: Clinical-stage immunology company developing infectious disease vaccines and therapeutics, including work on influenza, HIV, and pandemic threats. Comparable to UCI's infectious disease and pandemic preparedness focus across Picornaviridae and other virus families.
• Arcturus Therapeutics: Clinical-stage mRNA medicines company with proprietary lipid nanoparticle delivery platforms and a pipeline spanning infectious disease vaccines and rare disease therapeutics. Closely comparable to the UCI center's combination of mRNA-LNP delivery science and vaccine pipeline ambition.

Emerging players

• Walter Reed Army Institute of Research (WRAIR): U.S. military research institute with significant vaccine development programs for infectious diseases including pandemic preparedness, flaviviruses, and emerging threats. Comparable to UCI on federally funded vaccine R&D mandate and infectious disease focus, though focused on military and global health priorities.
• ImmunityBio: Clinical-stage immunotherapy company developing vaccines and cell therapies for cancer and infectious diseases. Comparable on the cancer vaccine and immune-engineering dimensions of UCI's research portfolio.

Broad incumbents

• BioNTech: Co-developer of the Pfizer-BioNTech COVID-19 mRNA vaccine and a leading commercial mRNA therapeutics company. Shares the mRNA-LNP technology lineage with the UCI Vaccine Center and applies it to cancer immunotherapies and infectious disease vaccines, representing the most direct commercial analog.
• Moderna: Commercial leader in mRNA-LNP vaccine technology, directly building on the foundational platform invented by Phil Felgner. Compares to UCI Vaccine Center on the underlying science but operates at commercial scale with approved COVID vaccines and a broad pipeline spanning infectious disease, oncology, and rare disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/vaccine-r-d-center

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaccine R & D Center